echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily Xinda Bio 3 new anti-tumor drugs have been approved by clinical trials.

    Research and development daily Xinda Bio 3 new anti-tumor drugs have been approved by clinical trials.

    • Last Update: 2020-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.10.12 Research and Development NEWS: Baishi Meishi Guibao S1P subjectulation agent is expected to open up a "new battleground" for inflammatory bowel disease; We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original) "Drug Research and Development" Hundred Mercy S1P subjectulation agent is expected to open up a "new battleground" for inflammatory bowel disease, Shishi Shiguibao announced that its oral S1P subject regulator Zeposia (ozanimod), in the treatment of adult patients with severe ulcerative colitis in the key Phase 3 clinical trials reached two major endpoints.
    compared to placebo, Zeposia significantly increased the proportion of patients who received clinical remission during the 10th week of induction therapy (18.4 percent to 6.0 percent ;p.lt;0001) and the 52nd week of the maintenance treatment period (37.0 percent to 18.5 percent ;p.lt;00001).
    Opdivo plus chemotherapy preoperative therapy to remove NSCLC Phase 3 Clinical: Significantly improved pCRBMS recently announced the evaluation of anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, Navulyu single The Phase 3 CheckMate-816 trial of anti-combination chemotherapy for new complementary therapy (preoperative therapy) in patients with excisive non-small cell lung cancer (NSCLC) reached its main endpoint: a significant statistical improvement in pathological complete remission (pCR).
    Sobi orphan drug for chemotherapy-induced platelet reduction phase III clinical failure Recently, Swiss orphan drugmaker Sobi announced the main results of an oral platelet-generating agent ®dotelet® for chemotherapy-induced platelet reduction in solid tumor patients.
    Although avatrombopag increased plateplate counts compared to placebos, the study did not reach the primary compound endpoint of avoiding plate plate plate infusion, reducing chemotherapy dose by 15% or more, and delaying chemotherapy dose by 4 days or more.
    Confang bio-anti-PD-1 mono-anti-registration clinical end-line third-line treatment of nasopharyngeal cancer 12, Kangfang Bio and China Biopharmaceutical jointly announced that anti-PD-1 monoantigen pympuli (Anico, research and development code-named AK105) for third-line treatment metastatic nasopharyngeal cancer registration clinical research, reached the objective mitigation rate of independent evaluation of the main endpoint.
    Pai Ampri monoantosis demonstrated good clinical efficacy and safety in NPC patients who had been treated with multiple lines in the past.
    Wesfarmers Mesa East debuted the latest research data on two trials of LENVIMA's joint KEYTRUDA in the LEAP (Lenphatini United Paboli Pearl Single Resistance) clinical research program for Class 7 tumor evaluation data Weishi Co., Ltd. and Mercadon.
    in phase II LEAP-004 trials, LENVIMA combined with KEYTRU in patients with non-removable or advanced melanoma who had previously experienced disease progression after treatment with anti-PD-1/PD-L1 The objective mitigation rate (ORR) of da is 21.4% (95% confidence interval (CI): 13.9-30.5); For past treatment of triple-negative breast cancer, ovarian cancer, stomach cancer, colorectal cancer (non-microsatellite high instability (non-MSI-H)/misalmutation repair gene normal (pMMR),) polygonal glial mother In patients with cytoblastoma and bile tube cancer, the ORR range of LENVIMA and KEYTRUDA was 9.7-32.3% (95% CI:2.0-51.4).
    Drug Approval: Ganley Pharmaceuticals FXR agonist ASC42 has been approved in the United States to conduct a NASH adaptation clinical trial Ganlai Pharmaceuticals today announced that its candidate drug for the treatment of non-alcoholic fatty hepatitis (NASH) ASC42 has been approved by the U.S. FDA for clinical trials.
    Xinda Bio3 anti-tumor new drugs approved clinical targets involving CTLA-4, GITR and PD-1CDE website latest publicity, Xinda Bio three new anti-tumor drugs obtained clinical trial implied license, including anti-CTLA-4 monoclonal antibody IBI310, anti-GITR monoclonal antibody IBI102 and PD-1 inhibitor Xindili monoant injection.
    , according to CDE's official website, this is the first time IBI102 has been approved clinically in China.
    Zee-Pharma liver cancer class 1 new drug listing application to be included in the priority review 12, CDE website latest publicity, Ze-Sezing Pharmaceutical Class 1 new drug toluene sulphate donaphine tablets listing application to be included in the priority review, the proposed adaptation of this application is - for the treatment of advanced (unable to operate or metastatic) liver cell carcinoma.
    Lisheng pharmaceutical pyridine tablets through generic drug consistency evaluation on the 12th, Lisheng Pharmaceuticals announced that the company recently received the State Drug Administration issued on the 2.5mg specifications of the drug supplemental application approval notice, the drug through generic quality and efficacy consistency evaluation.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.